Remedy with SR18662 drastically reduces advancement and proliferation of CRC cells. SR18662 displays enhanced efficacy in lowering viability of several CRC mobile traces. Move cytometry Assessment adhering to SR18662 treatment demonstrates an increase in cells captured in possibly S or G2/M phases on the mobile cycle and a major rise in the number